Investigational drug for colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug for colorectal cancer that has spread to the liver. It is designed for patients whose cancer hasn't responded to standard treatments and who have a specific genetic profile (pMMR).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and in good general health (able to do daily activities).
- Your colorectal cancer has spread to the liver and is a type called pMMR (meaning it has normal DNA repair mechanisms).
- You have already tried standard treatments like chemotherapy or targeted therapy and they stopped working, or you couldn't tolerate them, or you chose not to take them.
- You have at least one measurable tumor in the liver (seen on a CT scan).
- You have adequate organ function (like heart, liver, blood counts) and a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called YMN-A02 for people with advanced liver cancer that has not responded to standard targeted and immunotherapy treatments. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This study tests a new combination of two drugs (AK112 and VG2025) for people with colorectal cancer that has spread to the liver and has not responded to standard treatments. The goal is to see if this combination is safe and can help shrink or control the cancer.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
This trial tests a new drug, MRG007, combined with other treatments for advanced colorectal cancer. The goal is to see if this combination can shrink tumors or slow the cancer's growth when standard treatments have not worked.
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
Hear when a new Colorectal Cancer With Liver Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.